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Abstract 
Most drugs used in current medication for Covid-19 patient indicate several side effects due to 
the broad-spectrum drugs that affect the whole cells of human body (infected and healthy cells). 
Antiviral such as enzyme inhibitors, dideoxy, nucleoside/nucleotide analogs, amino acid analogs, 
even single chemical compound such as chloroquine phosphate, carboxylic acid type drugs and 
similar drugs may suppress some key molecules and changed pH not only in reactions which 
related to virus but also inevitably in the whole cells of human body. Based on all facts, then I 
designed the less cells destroying method to inhibit specifically SARS-CoV-2 replication in 
human cells.  Since the sequence of single strand positive sense of SARS-CoV-2 has determined, 
the mechanism of its replication inside human lung cells was also well understood, the transport 
membrane (endocytosis) of oligonucleotides are well known and the supportive biotechnological 
methods are adequate to produce this type of drug then I proposed this methods and design 
respectively: 1) Study the specific sequence of SARS-CoV-2 RNA.  2) Synthesize the 
oligonucleotide using nucleotides analogs (to produce fake primers) that can specifically attach 
to the specific sequence of SARS-CoV-2 RNA. 3) Conduct in vitro experiments using the fake 
primers produced and the infected cells, study the efficiency of endocytosis of fake primers 
through cell membrane and to know the best dosage that can inhibit the SARS-CoV-2 
replication.  4) Conduct clinical tests to the Covid-19 patients based on the in vitro test results 
(after passing the ethics protocol). So, the proposed novel narrow spectrum drug is the fake 
primer produced.    
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INTRODUCTION 
Currently, the drugs and vaccines 
that have been used and been developing 
for medication of Covid 19 patients are 
mostly based on broad spectrum drugs 
that effect both infected cells and healthy 
cells. The broad-spectrum drugs also 
produce some metabolites that could give 
negative effect to metabolism then leads 
to several symptoms and diseases. The 
utilization of broad spectrum drugs 
inevitably generate several side effects to 
patient because some drugs based on 
monomer such as nucleotide/ nucleoside 
analogs, dideoxynucleotide/ 
dideoxynucleoside, amino acid analogs, 
single chemical compound drugs 
(carboxylic acids, Chloroquine 
phosphate, etc.), and enzymes inhibitors.  
Those types of drugs mostly effect many 
biochemical reactions in not only 
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reactions which related to the virus but 
also the whole cells of human body. The 
drugs could not avoid to be involved in 
transcriptions, translations, replications, 
enzymes production, all enzymatic 
reactions in metabolism, biosynthesis of 
biomolecules in the whole cells of human 
body due to each of their function as 
biomolecules precursor in biosynthesis. 
The pH changes to be more alkaline also 
occur in all cells not only in the infected 
cells.  Besides that, a single type of 
monomer used such as nucleotide analog 
tends to cause fatal mutation by its end 
products in both infected cells and 
healthy cells. 
Meanwhile, the vaccines which 
have been developing and the fact that 
SARS-Cov-2 viruses have been mutating 
from Type A to Type B, then to Type C 
and predictably will continue mutating 
due to the lack of proof reading 
mechanism during transcription process 
of the virus RNA.  Some drugs also based 
on chemical molecule such as several 
types of carboxylic acid that responsible 
to inhibit specific reaction in virus before 
released from host cells exhibited several 
side effects to patient due to its 
metabolites produced in the cells.  
Therefore this short communication of 
review article aimed to propose a new 
method for designing and producing a 
novel narrow spectrum Covid-19 drug 
that will specifically react only inside the 
infected cells, relatively be more specific 
then predictably would reduce the side 
effects to the patients. 
 
METHODS  
This research was conducted by using 
literature review method. The results of this 
study were concluded as a Proposed Idea 
which can be used by all researchers who 
have been developing Covid-19 Drugs.  
 
LITERATURE REVIEW 
1. Structure of Coronaviruses 
Coronaviruses (CoVs) are single 
stranded RNA viruses that are included in 
the Coronavirinae subfamily, the 
Coronavirdiae family, the order of 
Nidovirales, which is surrounded protein 
envelope. CoV can be divided into four 
genes, namely, Alphacoronavirus (αCoV), 
Betacoronavirus (βCoV), Deltacoronavirus 
(δCoV), and Gammacoronavirus (γCoV). 
This group of viruses originates from 
zoonoses with αCoV and βCoV commonly 
found in bats and mice, while generally 
δCoV and γCoV are found in poultry species 
(Chan et al, 2013). The Coronaviruses have 
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spike proteins which mediates membrane 
fusion to bind to the cellular receptors 
(Figure 1). 
 
 
 
 
 
 
 
 
 
SARS CoV-2 virus is a 
betacoronavirus which was firstly revealed 
in Wuhan City, Hubei Province, China in 
December 2019 (Li et al, 2020). It contains 
four structural proteins, namely Spike (S), 
Envelope (E), Membrane (M), and 
Nucleocapside (N). The envelope of SARS 
CoV-2 was built from proteins S, M, and E. 
The M protein is the most responsible 
protein for the shape of the envelope. The E 
protein is the smallest structural protein. The 
S and M proteins are important during 
replication, while the N proteins responsible 
for the formation of nucleocapside in the 
envelope. The N proteins are also involved 
in the viral infection through assembly and 
budding of the CoV replication cycle. In 
addition, the name Coronavirus comes from 
the S proteins which surrounded the 
envelope creating a crown-like appearance 
(Chan et al, 2013). 
 
 
 
 
 
 
 
 
 
 
 
2. Genomic structure of SARS-CoV-2 
 The genome of SARS-CoV-2 is a 
single-stranded positive-sense RNA of 30kb 
(29891 nucleotides) encoding 9860 amino 
acids. The G + C content is 38%. The 
organization of SARS CoV-2 consists of 12 
open reading frames (ORFs), one set of nine 
sub genomic mRNAs, nine transcription-
regulatory parts, and 2 terminal regions 
which are untranslated. The first ORF 
contain almost two-thirds of the viral RNA 
that translates two polyproteins and encodes 
16 non-structural proteins (NSP). The 
remaining ORFs encode structural (S, E, M, 
N) and accessory proteins (Perlman et al, 
2009). In terms of whole genome sequence, 
it is revealed that SARS CoV-2 is closer to 
the SARS-like bat coronavirus (Chan et al, 
Spike (S) 
Nucleocapside (N) Membrane (M) 
RNA viral genome Envelope (E) 
Figure 1. Structure of Coronaviruses (Source: Cascella et al, 2020) 
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2020). Nevertheless, mutations are found in 
NSP2, NSP3, and S proteins, which 
determined the infectious capability and 
replication mechanism of SARS CoV-2 
(Angeletti et al, 2020). 
 
 
 
 
 
 
 
 
 
 
3. Mechanisms of SARS-CoV-2 infection 
There are three ways of SARS-CoV-
2 transmission: droplets, contact, and 
aerosol transmissions (Figure 3). Droplets 
transmission can occur when infected 
patients cough, or sneeze and the droplets 
are inhaled or ingested by other people 
nearby. Contact transmission can occur 
when a person touches the surface or object 
which previously contaminated with the 
virus, and afterwards touches his eyes, 
mouth, or nose. Meanwhile, aerosol 
transmission can occur when droplets mix 
into the air and forming aerosol which is 
then inhaled in high dose into the lungs of 
nearby people. The main pathogenesis of 
COVID-19 infection is severe pneumonia, 
together with acute cardiac injury (Cascella 
et al, 2020). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The incubation period of SARS-
CoV-2 infection ranges from 1 day to 14 
days, which is also associated with the age 
of the infected people (Li et al, 2020). Age 
of 60 and above usually has incubation 
period faster compared with others. After 
the virus enter the respiratory tract, it affects 
the alveoli. The epithelial cells in the lower 
respiratory tract helps the virus to attach to 
its receptor, hACE2, which is 
downregulated after the infection of SARS-
CoV-2. The binding of SARS-CoV-2 S 
protein is believed to be the virulence key 
factor for viral attachment and entry.  
 
Figure 2. Genome structure of Coronaviruses (Source: Cascella et al, 2020) 
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The S protein and hACE2 binding 
efficiency in SARS-CoV-2 infection is 10-
20-fold higher than that of SARS-CoV 
infection. However, which molecules 
facilitate the membrane of SARS-CoV-2 
endocytosis are still unclear. The S protein 
comprises S1 and S2 subunits. The subunit 
S1 is responsible for the binding via 
Receptor Binding Domain (RBD), while the 
subunit S2 helps the fusion of virus-cell 
membrane (Song et al, 2018). 
The genome RNA of CoV contains 
about 30kb nucleotides which encodes 
structural and non-structural proteins 
responsible for viral RNA synthesis, the so-
called replicase-transcriptase proteins. These 
replicase-transcriptase proteins are encoded 
in ORF1a and ORF1b which synthesized as 
pp1a and pp1ab. 
 
 
 
 
 
 
 
 
 
 
 
 
NSP1 to NSP11 are encoded in ORF1a, 
while NSP12 to NSP16 are encoded in 
ORF1b. The complex of replicase-
transcriptase (RTC) protein is composed of 
replicase-transcriptase protein together with 
other viral proteins and cellular proteins. 
This RTC is associated with double-
membrane vesicles. The NSP3, NSP6, and 
NSP6 are the anchor of pp1a/pp1ab to 
membranes during the first step of RTC 
formation (Perlman and Netland, 2009). The 
virion-containing vesicles fuse with the 
plasma membrane of the cell and release the 


Bat CoV 
Intermediate host 
Human to human 
transmission 
Incidental host, 
ACE2 receptor 
Direct contact 
Direct contact 
Droplet spread/ 
direct contact 
Figure 3. Transmission cycle of SARS-CoV-2 (Source: Cascella et al, 2020) 
AVOGADRO Jurnal Kimia, Volume 4, Nomor 1, Mei 2020, Hal 64-72    69 
 
  
virus which subsequently attach a new cell. 
So, the replication cycle is repeated. 
 
4. Current Treatments  
 Drugs and Vaccines that currently used 
to fight the Covid-19 pandemic as seen in 
Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Several treatments of Covid-19 (Source: Artis Ventures, 2020) 
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RESULTS AND DISCUSSIONS 
 Since the mechanism of SARS-Cov-
2 replication was well understood and also 
mostly the supportive biotechnology 
methods are sufficient to sequence the virus 
RNA, the availability of nucleotides analog,  
the technique to synthesis oligonucleotide as 
primer, then the fake primer that synthesis 
by using nucleotides analog can be 
produced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, the transport membrane and 
endocytosis of oligonucleotides were also 
known for up taking and trafficking of 
oligonucleotide in cytoplasm. Therefore, the 
fake primers produced would be the new 
drugs for Covid-19 patients. 
 The idea of using fake primer as the 
drug for Covid-19 patients based on 
following mechanism (Figure 5): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. (a). Viruses inject their RNA to cytosol of human lung cell. (b) Fake primer 
(oligonucleotide analog) attach to the virus RNA. (c) Fake primers attach to viruses RNAs then 
will stop the working of RNA dependent RNA polymerase inside the infected cell. (d) So, the 
new virions will not be formed. 
a 
b 
c d 
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The virus RNA which has an 
attached fake primer will not be processed 
further to produce vital protein for new 
virions. The aggregate of RNA and fake 
primer then naturally destroyed by cell’s 
mechanism. 
 
CONCLUSIONS 
I proposed the methods and design 
respectively: 1) Study the specific sequence 
of SARS-CoV-2 RNA.  2) Synthesize the 
oligonucleotide using nucleotides analogs 
(to produce fake primers) that can 
specifically attach to the specific sequence 
of SARS-CoV-2 RNA. 3) Conduct in vitro 
experiments using the fake primers 
produced and the infected cells, study the 
efficiency of endocytosis of fake primers 
through cell membrane and to know the best 
dosage that can inhibit the SARS-CoV-2 
replication.  4) Conduct clinical tests (after 
passing the ethics protocol) to the Covid-19 
patients based on the in vitro test results. So, 
the proposed novel narrow spectrum drug is 
the fake primer. 
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